Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis

JFerlayISoerjomataramMErvikGLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11. Lyon, France: International Agency for Research on Cancer; 2013; http://globocan.iarc.fr, 19 May 2014, date last accessed.

2010, Updated Japanese Urological Association Guidelines on prostate-specific antigen-based screening for prostate cancer in 2010, Int J Urol, 17, 830, 10.1111/j.1442-2042.2010.02613.x

Buford, 2010

Chou, 2011, Screening for prostate cancer: a review of the evidence for the U.S.: Preventive Services Task Force, Ann Intern Med, 155, 762, 10.7326/0003-4819-155-11-201112060-00375

Horwich, 2010, Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 21, v129, 10.1093/annonc/mdq174

Thompson, 2005, Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower, J Am Med Assoc, 294, 66, 10.1001/jama.294.1.66

Gulati, 2014, Individualized estimates of overdiagnosis in screen-detected prostate cancer, J Natl Cancer Inst, 106, 1, 10.1093/jnci/djt367

Thompson, 2006, Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial, J Natl Cancer Inst, 98, 529, 10.1093/jnci/djj131

Roobol, 2010, A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer, Eur Urol, 57, 79, 10.1016/j.eururo.2009.08.025

Nam, 2007, Assessing individual risk for prostate cancer, J Clin Oncol, 25, 3582, 10.1200/JCO.2007.10.6450

Schroder, 2008, The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: a systematic review, Eur Urol, 54, 274, 10.1016/j.eururo.2008.05.022

Shariat, 2008, Inventory of prostate cancer predictive tools, Curr Opin Urol, 18, 279, 10.1097/MOU.0b013e3282f9b3e5

Shariat, 2008, An updated catalog of prostate cancer predictive tools, Cancer, 113, 3075, 10.1002/cncr.23908

Shariat, 2008, Comparison of nomograms with other methods for predicting outcomes in prostate cancer: a critical analysis of the literature, Clin Cancer Res, 14, 4400, 10.1158/1078-0432.CCR-07-4713

Shariat, 2009, Critical review of prostate cancer predictive tools, Future Oncol, 5, 1555, 10.2217/fon.09.121

Liberati, 2009, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration, BMJ, 339, b2700, 10.1136/bmj.b2700

Wong, 2006, Comparison of top-performing search strategies for detecting clinically sound treatment studies and systematic reviews in MEDLINE and EMBASE, J Med Library Assoc, 94, 451

Davey, 2011, Characteristics of meta-analyses and their component studies in the Cochrane Database of Systematic Reviews:=a cross-sectional, descriptive analysis, BMC Med Res Methodol, 11, 160, 10.1186/1471-2288-11-160

Bouwmeester, 2012, Reporting and methods in clinical prediction research: a systematic review, PLoS Med, 9, 1, 10.1371/journal.pmed.1001221

Higgins, 2003, Measuring inconsistency in meta-analyses, BMJ, 327, 557, 10.1136/bmj.327.7414.557

Justice, 1999, Assessing the generalizability of prognostic information, Ann Intern Med, 130, 515, 10.7326/0003-4819-130-6-199903160-00016

Egger, 1997, Bias in meta-analysis detected by a simple, graphical test, BMJ, 315, 629, 10.1136/bmj.315.7109.629

Stephan, 2002, Multicenter evaluation of an artificial neural network to increase the prostate cancer detection rate and reduce unnecessary biopsies, Clin Chem, 48, 1279, 10.1093/clinchem/48.8.1279

Finne, 2004, Algorithms based on prostate-specific antigen (PSA), free PSA, digital rectal examination and prostate volume reduce false-positive PSA results in prostate cancer screening. International journal of cancer, J Int Cancer, 111, 310, 10.1002/ijc.20250

Karakiewicz, 2005, Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen, J Urol, 173, 1930, 10.1097/01.ju.0000158039.94467.5d

Chun, 2007, Development and external validation of an extended 10-core biopsy nomogram, Eur Urol, 52, 436, 10.1016/j.eururo.2006.08.039

Stephan, 2006, A (-5, -7) proPSA based artificial neural network to detect prostate cancer, Eur Urol, 50, 1014, 10.1016/j.eururo.2006.04.011

Stephan, 2007, Assay-specific artificial neural networks for five different PSA assays and populations with PSA 2–10 ng/ml in 4,480 men, World J Urol, 25, 95, 10.1007/s00345-006-0132-9

Chun, 2007, Initial biopsy outcome prediction--head-to-head comparison of a logistic regression-based nomogram versus artificial neural network, Eur Urol, 51, 1236, 10.1016/j.eururo.2006.07.021

Kawakami, 2008, Development, validation, and head-to-head comparison of logistic regression-based nomograms and artificial neural network models predicting prostate cancer on initial extended biopsy, Eur Urol, 54, 601, 10.1016/j.eururo.2008.01.017

Stephan, 2008, An artificial neural network for five different assay systems of prostate-specific antigen in prostate cancer diagnostics, BJU Int, 102, 799, 10.1111/j.1464-410X.2008.07765.x

Meijer, 2009, The value of an artificial neural network in the decision-making for prostate biopsies, World J Urol, 27, 593, 10.1007/s00345-009-0444-7

Stephan, 2010, Internal validation of an artificial neural network for prostate biopsy outcome, Int J Urol, 17, 62, 10.1111/j.1442-2042.2009.02417.x

Ecke, 2012, External validation of an artificial neural network and two nomograms for prostate cancer detection, ISRN Urol, 2012, 643181

Utsumi, 2009, External validation and head-to-head comparison of Japanese and Western prostate biopsy nomograms using Japanese data sets, Int J Urol, 16, 416, 10.1111/j.1442-2042.2009.02254.x

Stephan, 2011, Between-method differences in prostate-specific antigen assays affect prostate cancer risk prediction by nomograms, Clin Chem, 57, 995, 10.1373/clinchem.2010.151472

Ankerst, 2008, Predicting prostate cancer risk through incorporation of prostate cancer gene 3, J Urol, 180, 1303, 10.1016/j.juro.2008.06.038

Cavadas, 2010, Prostate cancer prevention trial and European randomized study of screening for prostate cancer risk calculators: a performance comparison in a contemporary screened cohort, Eur Urol, 58, 551, 10.1016/j.eururo.2010.06.023

Eyre, 2009, Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detection, J Urol, 182, 2653, 10.1016/j.juro.2009.08.056

Hernandez, 2009, Predicting the outcome of prostate biopsy: comparison of a novel logistic regression-based model, the prostate cancer risk calculator, and prostate-specific antigen level alone, BJU Int, 103, 609, 10.1111/j.1464-410X.2008.08127.x

Nam, 2011, Prospective multi-institutional study evaluating the performance of prostate cancer risk calculators, J Clin Oncol, 29, 2959, 10.1200/JCO.2010.32.6371

Ngo, 2011, The prostate cancer risk calculator from the Prostate Cancer Prevention Trial underestimates the risk of high grade cancer in contemporary referral patients, J Urol, 185, 483, 10.1016/j.juro.2010.09.101

Nguyen, 2010, Performance of prostate cancer prevention trial risk calculator in a contemporary cohort screened for prostate cancer and diagnosed by extended prostate biopsy, J Urol, 183, 529, 10.1016/j.juro.2009.10.007

Oliveira, 2011, Head-to-head comparison of two online nomograms for prostate biopsy outcome prediction, BJU Int, 107, 1780, 10.1111/j.1464-410X.2010.09727.x

Parekh, 2006, External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population, Urology, 68, 1152, 10.1016/j.urology.2006.10.022

Trottier, 2011, Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort, BJU Int, 108, E237, 10.1111/j.1464-410X.2011.10207.x

Ankerst, 2012, Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group, World J Urol, 30, 181, 10.1007/s00345-011-0818-5

Nomura, 2012, Development and external validation of a nomogram for predicting cancer probability at initial prostate biopsy using the life expectancy- and prostate volume-adjusted biopsy scheme, Prostate Cancer Prostatic Dis, 15, 202, 10.1038/pcan.2011.62

Roobol, 2012, Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators, Eur Urol, 61, 577, 10.1016/j.eururo.2011.11.012

van Vugt, 2011, Prediction of prostate cancer in unscreened men: external validation of a risk calculator, Eur J Cancer, 47, 903, 10.1016/j.ejca.2010.11.012

Yoon, 2012, Can the prostate risk calculator based on Western population be applied to Asian population?, Prostate, 72, 721, 10.1002/pros.21475

Stephan, 2007, Comparison of two different artificial neural networks for prostate biopsy indication in two different patient populations, Urology, 70, 596, 10.1016/j.urology.2007.04.004

Roobol, 2012, Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group, World J Urol, 30, 149, 10.1007/s00345-011-0804-y

Meigs, 1996, Interpreting results of prostate-specific antigen testing for early detection of prostate cancer, J Gen Intern Med, 11, 505, 10.1007/BF02599596

Lilja, 2008, Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nature reviews, Cancer, 8, 268

Vergouwe, 2010, External validity of risk models: Use of benchmark values to disentangle a case-mix effect from incorrect coefficients, Am J Epidemiol, 172, 971, 10.1093/aje/kwq223

Mistry, 2003, Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma, J Am Board Fam Pract, 16, 95, 10.3122/jabfm.16.2.95

Brindle, 2006, Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK, BJU Int, 98, 777, 10.1111/j.1464-410X.2006.06401.x

Salagierski, 2012, Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion, J Urol, 187, 795, 10.1016/j.juro.2011.10.133

Dijkstra, 2014, Clinical use of novel urine and blood based prostate cancer biomarkers: a review, Clin Biochem, 47, 889, 10.1016/j.clinbiochem.2013.10.023

Hansen, 2013, Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay, Eur Urol, 63, 201, 10.1016/j.eururo.2012.07.030

Leyten, 2014, Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer, Eur Urol, 65, 534, 10.1016/j.eururo.2012.11.014

2014, Prostate cancer: biomarkers PCA3 and TMPRSS2-ERG: better together. Nature reviews, Urology, 11, 129

Tomlins, 2011, Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA, Sci Translat Med, 3, 94ra72, 10.1126/scitranslmed.3001970

Ahmed, 2011, Characterizing clinically significant prostate cancer using template prostate mapping biopsy, J Urol, 186, 458, 10.1016/j.juro.2011.03.147

Thompson, 2004, Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter, N Engl J Med, 350, 2239, 10.1056/NEJMoa031918

Luboldt, 2007, Age-specific reference ranges for prostate-specific antigen as a marker for prostate cancer, EAU-EBU Update Series, 5, 38, 10.1016/j.eeus.2006.10.003

Lilja, 2011, Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50, Cancer, 117, 1210, 10.1002/cncr.25568